0001415889-22-012790.txt : 20221219
0001415889-22-012790.hdr.sgml : 20221219
20221219194815
ACCESSION NUMBER: 0001415889-22-012790
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221215
FILED AS OF DATE: 20221219
DATE AS OF CHANGE: 20221219
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gilliam Joseph E
CENTRAL INDEX KEY: 0001705850
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37463
FILM NUMBER: 221472563
MAIL ADDRESS:
STREET 1: C/O GLAUKOS CORPORATION
STREET 2: 229 AVENIDA FABRICANTE
CITY: SAN CLEMENTE
STATE: CA
ZIP: 92677
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: GLAUKOS Corp
CENTRAL INDEX KEY: 0001192448
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 229 AVENIDA FABRICANTE
CITY: SAN CLEMENTE
STATE: CA
ZIP: 92672
BUSINESS PHONE: 949-367-9600
MAIL ADDRESS:
STREET 1: 229 AVENIDA FABRICANTE
CITY: SAN CLEMENTE
STATE: CA
ZIP: 92672
FORMER COMPANY:
FORMER CONFORMED NAME: GLAUKOS CORP
DATE OF NAME CHANGE: 20020925
4
1
form4-12202022_121207.xml
X0306
4
2022-12-15
0001192448
GLAUKOS Corp
GKOS
0001705850
Gilliam Joseph E
C/O GLAUKOS CORPORATION
ONE GLAUKOS WAY
ALISO VIEJO
CA
92656
false
true
false
false
PRESIDENT & COO
Stock Option (Right to Buy)
55.18
2022-12-15
4
A
0
18295
0
A
2032-03-24
Common Stock
18295
18295
D
Represents a portion of an option to purchase shares of common stock previously granted by the Issuer on March 24, 2022, the vesting of which was subject to the Issuer's achievement of certain pre-determined operational targets over a multi-year performance period. The Compensation, Nominating and Governance Committee of the Issuer's Board of Directors determined on December 15, 2022 that certain of the operational targets had been achieved. The number of shares of common stock subject to the stock option as reported herein consists of the portion of the award that was earned based upon the achievement of the operational targets.
70% of the portion of the option reported herein will vest and become exercisable in January 2023, and the remaining 30% will vest and become exercisable in March 2023.
Diana Scherer, Attorney-in-Fact
2022-12-19